Funds raised by Sprint for Life are put to work finding new and innovative ways of diagnosing, treating and managing ovarian cancer. Each year, one or two $50,000 awards are given to MD Anderson faculty members to pursue specific research programs, with the combined goal of eliminating ovarian cancer.
Pratip Bhattacharya, Ph.D.
Metabolic Imaging of ovarian cancer
Kelsey Mathieu, Ph.D.
Early detection ovarian cancer through nanomagnetic relaxometry
Yunfei Wen, Ph.D.
Promoting autophagic catabolism in chemoresistant ovarian cancer
Alpa M. Nick, M.D.
Circulating tumor cells in ovarian cancer
Yuexin Liu, Ph.D.
Predicting therapy response in ovarian cancer
Wei Zhang, Ph.D.
MicroRNA therapy in ovarian cancer
Lois Ramondetta, M.D.
Targeting stress factors in ovarian cancer
Kathleen Schmeler, MD
Inherited and sporadic BRCA alterations in ovarian cancer
Vahid Afshar-Kharghan, M.D.
The role of complement pathway in ovarian cancer
Kwong K. Wong, Ph.D.
Understanding the molecular changes in cells that cause a rare ovarian cancer type: low grade serous carcinoma
Bulent Ozpolat, M.D., Ph.D.
Tumor-targeting siRNA – nanovectors for novel molecular therapy of metastatic ovarian cancer
Bryan Hennessy, M.D.
Proteomics to find markers of chemotherapy resistance in ovarian cancer
Michael Frumovitz, M.D., M.P.H.
The study of quality of life in women receiving second-line chemotherapy for recurrent ovarian cancer
Robert Luo, M.D., Ph.D.
Evaluating tumor suppressor genes and apoptosis-independent autophagic cell death in ovarian cancer cells
Lois Ramondetta, M.D.
Evaluating the role of spirituality in coping with and surviving ovarian cancer
Judith Ann Smith, Pharm.D., FCCP, BCOP
Evaluating the possible ways to reverse drug resistance during treatment of ovarian cancer
Anil Sood, M.D.
How the neuroendocrine system regulates growth factors in ovarian cancer patients
Charlotte Sun, Dr.P.H., M.P.H.
Evaluating quality of life of patients receiving high dose chemotherapy for ovarian cancer
Diane Bodurka, M.D.
Evaluating the preferences of toxicities for ovarian cancer patients on chemotherapy
Rosemarie Schmandt, Ph.D.
The study of genetic alterations in a specific class of molecules known as kinases, that are frequently observed in the development of ovarian cancer tumors